Inant human interleukin-12 in sufferers with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 2001, 82(1):70. 10. Motzer RJ, Rakhit A, Thompson JA, Nemunaitis J, Murphy BA, Ellerhorst J, Schwartz LH, Berg WJ, Bukowski RM: Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferonalpha 2a for sufferers with advanced renal cell carcinoma. J Interferon Cytokine Res 2001, 21(four):25763. 11. Darnell JE Jr: STATs and gene regulation. Science 1997, 277(5332):1630635. 12. Stephanou A, Latchman DS: STAT-1: a novel regulator of apoptosis. Int J Exp Pathol 2003, 84(6):23944. 13. Huang M, Web page C, Reynolds RK, Lin J: Constitutive activation of stat 3 oncogene solution in human ovarian carcinoma cells. Gynecol Oncol 2000, 79(1):673. 14. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr: Stat3 as an oncogene. Cell 1999, 98(3):29503. 15. Levy DE, Inghirami G: STAT3: a multifaceted oncogene. Proc Natl Acad Sci USA 2006, 103(27):101510152. 16. Huang S, Bucana CD, Van Arsdall M, Fidler IJ: Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 2002, 21(16):2504512. 17. Deng JY, Sun D, Liu XY, Pan Y, Liang H: STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. Globe J Gastroenterol 2010, 16(42):5380387. 18. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21(13):2000008. 19. Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M: Activation of signal transducer and activator of transcription three in renal cell carcinoma: a study of incidence and its association with pathological capabilities and clinical outcome. J Urol 2002, 168(two):76265.20. Chang KC, Wu MH, Jones D, Chen FF, Tseng YL: Activation of STAT3 in thymic epithelial tumours correlates with tumour sort and clinical behaviour.Abraxane J Pathol 2006, 210(2):22433. 21. David D, Rajappan LM, Balachandran K, Thulaseedharan JV, Nair AS, Pillai RM: Prognostic significance of STAT3 and phosphorylated STAT3 in human soft tissue tumors – a clinicopathological analysis. J Exp Clin Cancer Res 2011, 30:56. 22. Hunter CA: New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005, five(7):52131. 23. Leonard WJ, O’Shea JJ: Jaks and STATs: biological implications. Annu Rev Immunol 1998, 16:29322. 24. Hay ED: The mesenchymal cell, its role within the embryo, plus the remarkable signaling mechanisms that produce it. Dev Dyn 2005, 233(3):70620.Sevelamer hydrochloride 25.PMID:25040798 Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW: Epithelial esenchymal and mesenchymal pithelial transitions in carcinoma progression. J Cell Physiol 2007, 213(two):37483. 26. Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang XH, Wong YC, Guan XY, Man K, Chau KL, et al: Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 2006, 12(18):5369376. 27. Ho MY, Leu SJ, Sun GH, Tao MH, Tang SJ, Sun KH: IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J Immunol 2009, 183(ten):6217226. 28. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al: Mutational heterogeneity in cancer along with the search.